Co-Authors
This is a "connection" page, showing publications co-authored by FUNDA MERIC-BERNSTAM and KELLY K HUNT.
Connection Strength
8.201
-
Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009 Oct; 250(4):558-66.
Score: 0.365
-
Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer. 2003 Dec 01; 98(11):2522-3; author reply 2523-4.
Score: 0.243
-
Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer. 2003 Feb 15; 97(4):926-33.
Score: 0.230
-
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer. Ann Surg Oncol. 2023 Apr; 30(4):2111-2118.
Score: 0.229
-
Translation initiation in cancer: a novel target for therapy. Mol Cancer Ther. 2002 Sep; 1(11):971-9.
Score: 0.223
-
Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol. 2002 Jul; 9(6):543-9.
Score: 0.221
-
Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy. Ann Surg Oncol. 2002 Apr; 9(3):256-65.
Score: 0.217
-
HER2/neu in the management of invasive breast cancer. J Am Coll Surg. 2002 Apr; 194(4):488-501.
Score: 0.217
-
Effectiveness and Safety of Magseed-localization for Excision of Breast Lesions: A Prospective, Phase IV Trial. Ann Surg Open. 2020 Dec; 1(2).
Score: 0.198
-
Ductal carcinoma-in-situ: long-term results of breast-conserving therapy. Ann Surg Oncol. 2000 Oct; 7(9):656-64.
Score: 0.195
-
Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):45-50.
Score: 0.173
-
Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol. 2014 May; 25(5):1004-11.
Score: 0.124
-
Impact of identification of internal mammary sentinel lymph node metastasis in breast cancer patients. Ann Surg Oncol. 2014 Jan; 21(1):60-5.
Score: 0.120
-
Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Ann Surg. 2013 Feb; 257(2):173-9.
Score: 0.115
-
Other primary malignancies in breast cancer patients treated with breast conserving surgery and radiation therapy. Ann Surg Oncol. 2013 May; 20(5):1514-21.
Score: 0.114
-
Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population. J Am Coll Surg. 2013 Jan; 216(1):105-13.
Score: 0.113
-
Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer. Cancer. 2012 Dec 15; 118(24):6287-96.
Score: 0.110
-
Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012 Jun; 133(3):1131-41.
Score: 0.108
-
Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol. 2012 Feb 20; 30(6):600-7.
Score: 0.107
-
Triple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol. 2011 Oct; 18(11):3164-73.
Score: 0.105
-
Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. Ann Surg. 2011 Jul; 254(1):119-24.
Score: 0.103
-
Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol. 2011 Apr; 18(4):932-8.
Score: 0.101
-
Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg. 2011 Mar; 253(3):572-9.
Score: 0.101
-
Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. Cancer. 2011 Mar 01; 117(5):916-24.
Score: 0.098
-
Does blue dye contribute to success of sentinel node mapping for breast cancer? Ann Surg Oncol. 2010 Oct; 17 Suppl 3:280-5.
Score: 0.098
-
Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol. 2010 Oct; 17 Suppl 3:343-51.
Score: 0.098
-
Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila). 2010 Aug; 3(8):1026-34.
Score: 0.096
-
A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer. 2010 Jun 01; 116(11):2543-8.
Score: 0.095
-
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010 Apr 10; 28(11):1821-8.
Score: 0.094
-
Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer. 2009 Mar 01; 115(5):962-71.
Score: 0.088
-
Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol. 2008 Dec; 15(12):3369-77.
Score: 0.085
-
How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? Cancer. 2008 Jul 01; 113(1):30-7.
Score: 0.084
-
Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy. Cancer. 2008 Jun 15; 112(12):2646-54.
Score: 0.083
-
Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg. 2008 Jul; 196(1):81-7.
Score: 0.083
-
Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy. Am J Surg. 2007 Oct; 194(4):527-31.
Score: 0.079
-
Metastases to the breast from nonbreast solid neoplasms: presentation and determinants of survival. Cancer. 2007 Aug 15; 110(4):731-7.
Score: 0.079
-
Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007 Aug 15; 110(4):723-30.
Score: 0.079
-
Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer. 2007 Apr 01; 109(7):1255-63.
Score: 0.077
-
Role for intraoperative margin assessment in patients undergoing breast-conserving surgery. Ann Surg Oncol. 2007 Apr; 14(4):1458-71.
Score: 0.076
-
Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg. 2006 Oct; 192(4):552-5.
Score: 0.074
-
Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg. 2006 Oct; 203(4):475-80.
Score: 0.074
-
Use of lymphoscintigraphy defines lymphatic drainage patterns before sentinel lymph node biopsy for breast cancer. J Am Coll Surg. 2006 Jul; 203(1):64-72.
Score: 0.072
-
Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol. 2006 Mar; 13(3):310-20.
Score: 0.071
-
Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence. Cancer. 2005 Aug 01; 104(3):479-90.
Score: 0.068
-
Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer. 2005 Jul 01; 104(1):20-9.
Score: 0.068
-
Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 2005 Apr 15; 103(8):1581-6.
Score: 0.067
-
Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma. Cancer. 2005 Apr 01; 103(7):1323-9.
Score: 0.067
-
Paget's disease of the breast: there is a role for breast-conserving therapy. Ann Surg Oncol. 2005 May; 12(5):391-7.
Score: 0.067
-
Lymphatic drainage patterns on early versus delayed breast lymphoscintigraphy performed after injection of filtered Tc-99m sulfur colloid in breast cancer patients undergoing sentinel lymph node biopsy. Clin Nucl Med. 2005 Jan; 30(1):11-5.
Score: 0.066
-
Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer. 2004 Nov 01; 101(9):1977-86.
Score: 0.065
-
Axillary Nodal Metastases Conversion and Perioperative Complications with Neoadjuvant Pembrolizumab Therapy in Triple-Negative Breast Cancer. Ann Surg Oncol. 2024 Feb; 31(2):974-980.
Score: 0.061
-
Impact of clinicopathological factors on sensitivity of axillary ultrasonography in the detection of axillary nodal metastases in patients with breast cancer. Ann Surg Oncol. 2003 Nov; 10(9):1025-30.
Score: 0.061
-
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers. Cancer Res. 2023 10 02; 83(19):3264-3283.
Score: 0.060
-
To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer? Ann Surg Oncol. 2023 Dec; 30(13):8327-8334.
Score: 0.060
-
Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer. 2002 Nov 15; 95(10):2059-67.
Score: 0.057
-
Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer. 2002 Sep 01; 95(5):1120-6.
Score: 0.056
-
Breast cancer on the world wide web: cross sectional survey of quality of information and popularity of websites. BMJ. 2002 Mar 09; 324(7337):577-81.
Score: 0.054
-
Radiofrequency ablation of early-stage invasive breast tumors: an overview. Cancer J. 2002 Mar-Apr; 8(2):177-80.
Score: 0.054
-
Utility of breast sentinel lymph node biopsy using day-before-surgery injection of high-dose 99mTc-labeled sulfur colloid. Ann Surg Oncol. 2001 Dec; 8(10):821-7.
Score: 0.053
-
Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2021 Oct; 28(10):5477-5485.
Score: 0.052
-
Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas. J Clin Oncol. 2000 Oct 01; 18(19):3378-83.
Score: 0.049
-
Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer. Ann Surg Oncol. 2000 Jul; 7(6):435-40.
Score: 0.048
-
Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Clin Cancer Res. 2018 12 15; 24(24):6594-6610.
Score: 0.042
-
Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy. Ann Surg Oncol. 2017 Mar; 24(3):652-659.
Score: 0.037
-
Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. Int J Radiat Oncol Biol Phys. 2016 11 01; 96(3):637-44.
Score: 0.036
-
A Cost Analysis of Preoperative Breast MRI Use for Patients with Invasive Lobular Cancer. Ann Surg Oncol. 2016 Jan; 23(1):23-9.
Score: 0.034
-
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol. 2013 Dec; 14(13):1317-25.
Score: 0.030
-
Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? Ann Surg Oncol. 2013 Dec; 20(13):4103-12.
Score: 0.030
-
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol. 2013 Aug; 24(8):1999-2004.
Score: 0.029
-
Primary tumor extirpation in breast cancer patients who present with stage IV disease is associated with improved survival. Ann Surg Oncol. 2013 Jun; 20(6):1893-9.
Score: 0.029
-
American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol. 2012 Oct; 19(10):3144-51.
Score: 0.028
-
Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol. 2012 Nov; 19(12):3777-84.
Score: 0.027
-
Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res. 2012 May 23; 14(3):R82.
Score: 0.027
-
Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res. 2012 May 23; 14(3):R83.
Score: 0.027
-
Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer. 2012 Oct 15; 118(20):4936-43.
Score: 0.027
-
Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery. 2012 May; 151(5):710-6.
Score: 0.027
-
Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node. Ann Surg. 2012 Jan; 255(1):109-15.
Score: 0.027
-
Prospective evaluation of the nipple-areola complex sparing mastectomy for risk reduction and for early-stage breast cancer. Ann Surg Oncol. 2012 Apr; 19(4):1137-44.
Score: 0.026
-
Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol. 2011 Sep; 18(9):2407-12.
Score: 0.026
-
Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol. 2012 Mar; 19(3):901-7.
Score: 0.026
-
Wide-field imaging of fluorescent deoxy-glucose in ex vivo malignant and normal breast tissue. Biomed Opt Express. 2011 Jun 01; 2(6):1514-23.
Score: 0.025
-
Sentinel lymph node dissection is technically feasible in older breast cancer patients. Clin Breast Cancer. 2010 Dec 01; 10(6):477-82.
Score: 0.025
-
High-resolution fiber optic microscopy with fluorescent contrast enhancement for the identification of axillary lymph node metastases in breast cancer: a pilot study. Biomed Opt Express. 2010 Sep 16; 1(3):911-922.
Score: 0.024
-
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer. 2011 Jan 01; 117(1):39-47.
Score: 0.024
-
Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. Ann Surg Oncol. 2010 Dec; 17(12):3252-8.
Score: 0.024
-
Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. Cancer. 2010 Jun 15; 116(12):2878-83.
Score: 0.024
-
Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010 Jun 15; 116(12):2884-9.
Score: 0.024
-
Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol. 2010 Nov; 17(11):2899-908.
Score: 0.024
-
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res. 2009 Dec 01; 15(23):7381-8.
Score: 0.023
-
False negative rate of sentinel lymph node biopsy in multicentric and multifocal breast cancers may be higher in cases with large additive tumor burden. Breast J. 2009 Nov-Dec; 15(6):645-8.
Score: 0.023
-
Intra-individual comparison of lymphatic drainage patterns using subareolar and peritumoral isotope injection for breast cancer. Ann Surg Oncol. 2010 Jan; 17(1):220-7.
Score: 0.023
-
Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. Am J Surg. 2009 Nov; 198(5):720-5.
Score: 0.022
-
Margin assessment after neoadjuvant chemotherapy in invasive lobular cancer. Am J Surg. 2009 Sep; 198(3):387-91.
Score: 0.022
-
A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. Cancer. 2009 Apr 01; 115(7):1555-62.
Score: 0.022
-
Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Ann Surg Oncol. 2009 Jun; 16(6):1606-11.
Score: 0.022
-
Radiation use and long-term survival in breast cancer patients with T1, T2 primary tumors and one to three positive axillary lymph nodes. Int J Radiat Oncol Biol Phys. 2008 Jul 15; 71(4):1022-7.
Score: 0.020
-
Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy. Cancer. 2007 Dec 01; 110(11):2542-50.
Score: 0.020
-
Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged
View in: PubMed
Score: 0.020
Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis. Int J Radiat Oncol Biol Phys. 2007 Feb 01; 67(2):490-6.
Score: 0.019
Is intraoperative touch imprint cytology of sentinel lymph nodes in patients with breast cancer cost effective? Cancer. 2006 Nov 15; 107(10):2328-36.
Score: 0.019
Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer. 2006 Oct 01; 107(7):1440-7.
Score: 0.019
Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center. Am J Surg. 2006 Oct; 192(4):541-4.
Score: 0.019
Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol. 2006 Nov; 13(11):1443-9.
Score: 0.018
The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2006 Sep 15; 107(6):1248-54.
Score: 0.018
Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006 Sep; 244(3):464-70.
Score: 0.018
Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys. 2006 Oct 01; 66(2):352-7.
Score: 0.018
Polymorphisms and haplotypes of the NBS1 gene are associated with risk of sporadic breast cancer in non-Hispanic white women
View in: PubMed
Score: 0.018
Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol. 2006 Jun; 13(6):776-82.
Score: 0.018
Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg. 2006 Feb; 243(2):257-64.
Score: 0.018
Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer. 2006 Jan 01; 106(1):42-50.
Score: 0.018
Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg. 2006 Jan; 243(1):96-101.
Score: 0.018
Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node. Am J Surg. 2005 Oct; 190(4):598-601.
Score: 0.017
Determinants of mastectomy in breast conservation therapy candidates. Am J Surg. 2005 Oct; 190(4):602-5.
Score: 0.017
Immediate breast reconstruction can impact postmastectomy irradiation. Am J Clin Oncol. 2005 Oct; 28(5):485-94.
Score: 0.017
Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol. Cancer. 2005 Aug 15; 104(4):692-9.
Score: 0.017
Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005 Apr; 200(4):516-26.
Score: 0.017
Breast conservation after neoadjuvant chemotherapy. Cancer. 2005 Feb 15; 103(4):689-95.
Score: 0.017
The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer. Cancer. 2004 Oct 01; 101(7):1514-23.
Score: 0.016
Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma. Cancer. 2004 Sep 15; 101(6):1330-7.
Score: 0.016
Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol. 2004 Sep; 11(9):854-60.
Score: 0.016
Feasibility of breast-conserving surgery for patients with breast carcinoma associated with nipple discharge. Cancer. 2004 Aug 01; 101(3):508-17.
Score: 0.016
Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields. Int J Radiat Oncol Biol Phys. 2004 Jul 15; 59(4):1074-9.
Score: 0.016
Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004 Jun 15; 22(12):2303-12.
Score: 0.016
Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer. 2004 Mar 01; 100(5):942-9.
Score: 0.015
Potential applicability of balloon catheter-based accelerated partial breast irradiation after conservative surgery for breast carcinoma. Cancer. 2004 Feb 01; 100(3):490-8.
Score: 0.015
Anaphylactoid reactions to isosulfan blue dye during breast cancer lymphatic mapping in patients given preoperative prophylaxis. J Clin Oncol. 2004 Feb 01; 22(3):567-8.
Score: 0.015
Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2003 Oct 01; 57(2):336-44.
Score: 0.015
Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery. Am J Surg. 2003 Oct; 186(4):371-7.
Score: 0.015
Chest wall recurrence after mastectomy does not always portend a dismal outcome. Ann Surg Oncol. 2003 Jul; 10(6):628-34.
Score: 0.015
Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol. 2003 Apr; 10(3):248-54.
Score: 0.015
Histologic localization of sentinel lymph node metastases in breast cancer. Am J Surg Pathol. 2003 Mar; 27(3):385-9.
Score: 0.014
Surgical decision making and factors determining a diagnosis of breast carcinoma in women presenting with nipple discharge. J Am Coll Surg. 2003 Mar; 196(3):354-64.
Score: 0.014
Breast-conservation therapy in early-stage breast cancer patients with a positive family history. Ann Surg Oncol. 2002 Nov; 9(9):912-9.
Score: 0.014
Treatment and outcome of patients with intracystic papillary carcinoma of the breast. Am J Surg. 2002 Oct; 184(4):364-8.
Score: 0.014
Breast conservation therapy as a treatment option for the elderly. The M. D. Anderson experience. Cancer. 2001 Sep 01; 92(5):1092-100.
Score: 0.013